Verona Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:I9SA Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
06 Dec 24	Sell€4,178,342	Mark Hahn	Individual	110,245	€37.92
06 Dec 24	Sell€4,124,721	David Zaccardelli	Individual	108,834	€37.92
02 Dec 24	Sell€597,691	David Zaccardelli	Individual	15,666	€38.16
02 Dec 24	Sell€540,125	Mark Hahn	Individual	14,155	€38.16
26 Nov 24	Sell€11,460	Mark Hahn	Individual	300	€38.20
25 Nov 24	Sell€1,122,130	Kathleen Rickard	Individual	30,000	€37.40
25 Nov 24	Sell€7,631	David Zaccardelli	Individual	200	€38.16
18 Nov 24	Buy€31,505	David Ebsworth	Individual	2,500	€12.60
11 Nov 24	Sell€11,267	Mark Hahn	Individual	300	€37.56
11 Nov 24	Sell€11,267	David Zaccardelli	Individual	300	€37.56
06 Nov 24	Buy€184,856	Christina Ackermann	Individual	5,235	€35.31
06 Nov 24	Buy€175,999	David Ebsworth	Individual	4,920	€35.77
04 Nov 24	Sell€522,063	Mark Hahn	Individual	16,209	€32.24
04 Nov 24	Sell€568,237	David Zaccardelli	Individual	17,629	€32.27
25 Oct 24	Sell€585,720	David Zaccardelli	Individual	18,102	€32.36
25 Oct 24	Sell€584,671	Mark Hahn	Individual	18,070	€32.36
22 Oct 24	Sell€2,130,529	Mark Hahn	Individual	525,768	€4.06
22 Oct 24	Sell€2,083,793	David Zaccardelli	Individual	514,152	€4.06
11 Sep 24	Sell€2,047,155	Mark Hahn	Individual	600,000	€3.41
11 Sep 24	Sell€2,047,373	David Zaccardelli	Individual	600,000	€3.41
13 Aug 24	Sell€1,164,441	Mark Hahn	Individual	49,800	€23.74
12 Aug 24	Buy€94,486	David Ebsworth	Individual	4,500	€21.00
12 Aug 24	Sell€4,580	Mark Hahn	Individual	200	€22.90
12 Aug 24	Sell€4,580	David Zaccardelli	Individual	200	€22.90
03 May 24	Sell€65,939	Kathleen Rickard	Individual	4,531	€14.55

Insider Trading Volume

Insider Buying: I9SA insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of I9SA?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	3,356,208	4.1%
General Public	3,902,321	4.77%
Hedge Funds	4,215,973	5.15%
VC/PE Firms	18,096,325	22.1%
Institutions	52,260,342	63.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 74.15% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
7.72%	Perceptive Advisors LLC	6,315,933	€296.4m	160%	6.96%
7.57%	RA Capital Management, L.P.	6,195,639	€290.8m	-29.7%	3.65%
6.82%	New Enterprise Associates, Inc.	5,584,753	€262.1m	0%	13.91%
5.15%	Maverick Capital, Ltd.	4,215,973	€197.9m	36.3%	3.58%
4.62%	OrbiMed Advisors LLC	3,777,778	€177.3m	0%	2.55%
4.34%	Vivo Capital, LLC	3,549,779	€166.6m	-46.3%	13.95%
4.14%	Frazier Life Sciences Management, LP	3,383,950	€158.8m	2.1%	6.12%
3.89%	Deep Track Capital, LP	3,180,025	€149.2m	-20.5%	4.69%
2.96%	Eventide Asset Management, LLC	2,425,846	€113.9m	360%	2.0%
2.65%	Federated Hermes, Inc.	2,167,900	€101.7m	0.2%	0.25%
2.3%	Wellington Management Group LLP	1,878,632	€88.2m	19.6%	0.01%
2.24%	Octagon Capital Advisors LP	1,835,200	€86.1m	-3.17%	14.03%
2.13%	Jennison Associates LLC	1,740,886	€81.7m	54.3%	0.05%
1.76%	Caligan Partners, LP	1,436,878	€67.4m	-22.1%	20.46%
1.75%	Hood River Capital Management LLC	1,433,934	€67.3m	35%	1.04%
1.71%	David Zaccardelli	1,400,594	€65.7m	-9.83%	no data
1.63%	T. Rowe Price Group, Inc.	1,335,194	€62.7m	40.6%	0.01%
1.57%	Mark Hahn	1,286,717	€60.4m	-10.6%	no data
1.49%	Bellevue Asset Management AG	1,220,059	€57.3m	7.57%	0.7%
1.44%	Citadel Advisors LLC	1,178,022	€55.3m	1,050%	0.06%
1.36%	Aisling Capital Management LP	1,115,352	€52.3m	0%	18.18%
1.36%	Loomis Sayles & Company, L.P.	1,111,096	€52.1m	0%	0.06%
1.27%	Janus Henderson Group plc	1,042,795	€48.9m	-4.51%	0.02%
1.2%	Rice Hall James & Associates, LLC	985,076	€46.2m	4.84%	2.45%
1.07%	American Century Investment Management Inc	876,604	€41.1m	-0.16%	0.02%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/03 10:53
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Verona Pharma plc is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Patrick Trucchio	Berenberg
Thomas Shrader	BTIG
Edward Nash	Canaccord Genuity